Table 1 Clinical characteristics of the study population at baseline categorized according to SDMA and ADMA values below or above the median
Characteristics | All participants (n = 200) | Symmetric dimethylarginine | p value | Asymmetric dimethylarginine | p value | ||
|---|---|---|---|---|---|---|---|
<0.4525 µmol/l (n = 100) | ≥0.4525 µmol/l (n = 100) | <0.4625 µmol/l (n = 100) | ≥0.4625 µmol/l (n = 100) | ||||
Male, n (%) | 152 (76) | 76 (76) | 75 (75) | 0.87 | 77 (23) | 74 (74) | 0.62 |
Age (years) | 59 ± 9 | 56.4 ± 9.2 | 60.9 ± 7.6 | <0.001 | 57.2 ± 9.8 | 60.1 ± 7.3 | 0.015 |
Known duration of diabetes (years) | 13 ± 7 | 10.8 ± 6.6 | 14.8 ± 7.6 | <0.001 | 11.7 ± 7.3 | 13.9 ± 7.3 | 0.033 |
Body mass index (kg/m2) | 32.6 ± 5.8 | 33.0 ± 5.3 | 32.1 ± 6.2 | 0.24 | 32.3 ± 4.8 | 32.8 ± 6.6 | 0.48 |
HbA1c (%) | 7.9 ± 1.3 | 7.93 ± 1.36 | 7.80 ± 1.34 | 0.49 | 7.92 ± 1.41 | 7.81 ± 1.29 | 0.55 |
HbA1c (mmol/mol) | 63 ± 14 | 63 ± 14.9 | 62 ± 14.6 | 0.49 | 63 ± 15.4 | 62 ± 14.1 | 0.55 |
Urinary albumin excretion rate (mg/24-h) | 103 (39–230) | 104.5 (47.9–219.8) | 98.0 (38.0–241.0) | 0.86 | 80.5 (33.0–176.9) | 133.0 (56.0–303.0) | 0.011 |
P-creatinine (μmol/L) | 76 ± 18 | 67.0 ± 13.8 | 85.9 ± 17.4 | <0.001 | 72.0 ± 17.4 | 80.9 ± 18.2 | <0.001 |
eGFR (ml/min/1.73 m2) | 130 ± 17 | 99.3 ± 13.0 | 79.7 ± 15.6 | <0.001 | 94.6 ± 16.9 | 84.4 ± 16.3 | <0.001 |
Systolic blood pressure (mmHg) | 152 ± 76 | 133 ± 18 | 127 ± 16 | 0.012 | 130 ± 17 | 130 ± 17 | 0.60 |
Diastolic blood pressure (mmHg) | 75 ± 11 | 77 ± 11 | 73 ± 11 | 0.016 | 76 ± 11 | 73 ± 11 | 0.051 |
LDL cholesterol (mmol/L) | 1.85 ± 0.78 | 1.90 ± 0.88 | 1.81 ± 0.67 | 0.39 | 1.81 ± 0.78 | 1.90 ± 0.78 | 0.45 |
Current smoker, n (%) | 59 (30) | 34 (34) | 25 (25) | 0.16 | 31 (31) | 28 (28) | 0.64 |
Treatment with | |||||||
 Oral antidiabetic, n (%) | 170 (85) | 87 (87) | 83 (83) | 0.43 | 89 (89) | 81 (81) | 0.11 |
 Insulin, n (%) | 124 (62) | 58 (58) | 66 (66) | 0.24 | 59 (59) | 65 (65) | 0.38 |
 Antihypertensive drugs, n (%) | 198 (99) | 100 (100) | 98 (98) | 0.16 | 99 (99) | 99 (99) | 1.00 |
 RAAS blockade, n (%) | 196 (98) | 96 (96) | 100 (100) | 0.043 | 98 (98) | 98 (98) | 1.00 |
 Beta-blocker, n (%) | 27 (14) | 9 (9) | 18 (18) | 0.063 | 11 (11) | 16 (16) | 0.31 |
 Calcium channel blockers, n (%) | 80 (40) | 43 (43) | 37 (37) | 0.39 | 36 (36) | 44 (44) | 0.25 |
 Diuretics, n (%) | 128 (64) | 57 (57) | 41 (41) | 0.039 | 63 (63) | 65 (65) | 0.77 |
 Statin, n (%) | 189 (95) | 94 (94) | 95 (95) | 0.76 | 97 (97) | 92 (92) | 0.12 |
 Aspirin, n (%) | 183 (92) | 92 (92) | 91 (91) | 0.80 | 90 (90) | 93 (93) | 0.45 |